TY - JOUR
T1 - Use of antiherpes drugs and the risk of Kaposi's sarcoma
T2 - Data from the multicenter AIDS Cohort Study
AU - Glesby, Marshall J.
AU - Hoover, Donald R.
AU - Weng, Shigui
AU - Graham, Neil M.H.
AU - Phair, John P.
AU - Detels, Roger
AU - Ho, Monto
AU - Saah, Alfred J.
PY - 1996
Y1 - 1996
N2 - To determine if use of antiherpes drugs protects against the development of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual men with AIDS from the Multicenter AIDS Cohort Study were analyzed. In nested case-control analysis, neither acyclovir use for human immunodeficiency virus infection (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.56-1.26; P = .39) nor acyclovir use for any indication (OR, 1.02; 95% CI, 0.76-1.38; P = .89) was associated with a reduced risk of KS as initial AIDS diagnosis. In longitudinal analysis, acyclovir was also not protective against developing KS as a late manifestation of AIDS (after initial non-KS AIDS diagnosis). Among men with cytomegalovirus disease, ganciclovir use (relative risk [RR], 0.56; 95% CI, 0.22-1.44; P = .23) and foscarnet use (RR, 0.40; 95% CI, 0.051-3.10; P = .38) were associated (although not significantly) with a reduced risk of KS. Thus, acyclovir use does not appear to reduce the risk of KS, but further study of other antiherpes drugs such as ganciclovir and foscarnet is warranted.
AB - To determine if use of antiherpes drugs protects against the development of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual men with AIDS from the Multicenter AIDS Cohort Study were analyzed. In nested case-control analysis, neither acyclovir use for human immunodeficiency virus infection (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.56-1.26; P = .39) nor acyclovir use for any indication (OR, 1.02; 95% CI, 0.76-1.38; P = .89) was associated with a reduced risk of KS as initial AIDS diagnosis. In longitudinal analysis, acyclovir was also not protective against developing KS as a late manifestation of AIDS (after initial non-KS AIDS diagnosis). Among men with cytomegalovirus disease, ganciclovir use (relative risk [RR], 0.56; 95% CI, 0.22-1.44; P = .23) and foscarnet use (RR, 0.40; 95% CI, 0.051-3.10; P = .38) were associated (although not significantly) with a reduced risk of KS. Thus, acyclovir use does not appear to reduce the risk of KS, but further study of other antiherpes drugs such as ganciclovir and foscarnet is warranted.
UR - http://www.scopus.com/inward/record.url?scp=0029843883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029843883&partnerID=8YFLogxK
U2 - 10.1093/infdis/173.6.1477
DO - 10.1093/infdis/173.6.1477
M3 - Article
C2 - 8648224
AN - SCOPUS:0029843883
SN - 0022-1899
VL - 173
SP - 1477
EP - 1480
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -
